StreetInsider.com News Articles

EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots

Mon, 22 Jun 2026 09:00:00 -0400

CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that EverythingALS will host a conversation built around a look at emerging data on PrimeC and what it may mean for the science of ALS and the people living with it.

Event details:

Date: June 24, 2026
Time: 7 pm

EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots

Mon, 22 Jun 2026 09:00:00 -0400

Event details:

Date: June 24, 2026
Time: 7 pm

EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots

Mon, 22 Jun 2026 09:00:00 -0400

Event details:

Date: June 24, 2026
Time: 7 pm

EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots

Mon, 22 Jun 2026 09:00:00 -0400

Event details:

Date: June 24, 2026
Time: 7 pm

EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots

Mon, 22 Jun 2026 09:00:00 -0400

Event details:

Date: June 24, 2026
Time: 7 pm

EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots

Mon, 22 Jun 2026 09:00:00 -0400

Event details:

Date: June 24, 2026
Time: 7 pm

EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots

Mon, 22 Jun 2026 09:00:00 -0400

Event details:

Date: June 24, 2026
Time: 7 pm

EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots

Mon, 22 Jun 2026 09:00:00 -0400

Event details:

Date: June 24, 2026
Time: 7 pm

EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots

Mon, 22 Jun 2026 09:00:00 -0400

Event details:

Date: June 24, 2026
Time: 7 pm

EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots

Mon, 22 Jun 2026 09:00:00 -0400

Event details:

Date: June 24, 2026
Time: 7 pm

EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots

Mon, 22 Jun 2026 09:00:00 -0400

Event details:

Date: June 24, 2026
Time: 7 pm

EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots

Mon, 22 Jun 2026 09:00:00 -0400

Event details:

Date: June 24, 2026
Time: 7 pm

NeuroSense receives South Korean patent for ALS drug PrimeC

Thu, 11 Jun 2026 09:02:05 -0400

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced that the Korean Intellectual Property Office has issued Korean Patent Number 10-2969898 covering the composition of PrimeC, the company's drug candidate for treating amyotrophic lateral sclerosis.

The patent covers PrimeC's tablet formulation, manufacturing process, pharmacokinetic characteristics, and pharmaceutical use for ALS treatment. Patent protection in South Korea is expected to extend through 2042.

"This patent grant further strengthens our growing global intellectual property estate surrounding PrimeC," said Alon Ben-Noon, Chief Executive Officer of NeuroSense. "South Korea is an important pharmaceutical market, and this milestone reflects the continued recognition of the novelty and proprietary nature of PrimeC

NeuroSense receives South Korean patent for ALS drug PrimeC

Thu, 11 Jun 2026 09:02:05 -0400

NeuroSense receives South Korean patent for ALS drug PrimeC

Thu, 11 Jun 2026 09:02:05 -0400

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

Thu, 11 Jun 2026 09:00:00 -0400

Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS
Expands intellectual property protection in one of the world's leading pharmaceutical markets, following recent patent advancements in Japan, Brazil, Australia and the United States
Further strengthens global patent portfolio as NeuroSense prepares to initiate Phase 3 development of PrimeC

CAMBRIDGE, Mass., June 11, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases,

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

Thu, 11 Jun 2026 09:00:00 -0400

Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS
Expands intellectual property protection in one of the world's leading pharmaceutical markets, following recent patent advancements in Japan, Brazil, Australia and the United States
Further strengthens global patent portfolio as NeuroSense prepares to initiate Phase 3 development of PrimeC

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

Thu, 11 Jun 2026 09:00:00 -0400

Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS
Expands intellectual property protection in one of the world's leading pharmaceutical markets, following recent patent advancements in Japan, Brazil, Australia and the United States
Further strengthens global patent portfolio as NeuroSense prepares to initiate Phase 3 development of PrimeC

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

Thu, 11 Jun 2026 09:00:00 -0400

Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS
Expands intellectual property protection in one of the world's leading pharmaceutical markets, following recent patent advancements in Japan, Brazil, Australia and the United States
Further strengthens global patent portfolio as NeuroSense prepares to initiate Phase 3 development of PrimeC

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

Thu, 11 Jun 2026 09:00:00 -0400

Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS
Expands intellectual property protection in one of the world's leading pharmaceutical markets, following recent patent advancements in Japan, Brazil, Australia and the United States
Further strengthens global patent portfolio as NeuroSense prepares to initiate Phase 3 development of PrimeC

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

Thu, 11 Jun 2026 09:00:00 -0400

Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS
Expands intellectual property protection in one of the world's leading pharmaceutical markets, following recent patent advancements in Japan, Brazil, Australia and the United States
Further strengthens global patent portfolio as NeuroSense prepares to initiate Phase 3 development of PrimeC

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

Thu, 11 Jun 2026 09:00:00 -0400

Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS
Expands intellectual property protection in one of the world's leading pharmaceutical markets, following recent patent advancements in Japan, Brazil, Australia and the United States
Further strengthens global patent portfolio as NeuroSense prepares to initiate Phase 3 development of PrimeC

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

Thu, 11 Jun 2026 09:00:00 -0400

Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS
Expands intellectual property protection in one of the world's leading pharmaceutical markets, following recent patent advancements in Japan, Brazil, Australia and the United States
Further strengthens global patent portfolio as NeuroSense prepares to initiate Phase 3 development of PrimeC

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

Thu, 11 Jun 2026 09:00:00 -0400

Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS
Expands intellectual property protection in one of the world's leading pharmaceutical markets, following recent patent advancements in Japan, Brazil, Australia and the United States
Further strengthens global patent portfolio as NeuroSense prepares to initiate Phase 3 development of PrimeC

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

Thu, 11 Jun 2026 09:00:00 -0400

Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS
Expands intellectual property protection in one of the world's leading pharmaceutical markets, following recent patent advancements in Japan, Brazil, Australia and the United States
Further strengthens global patent portfolio as NeuroSense prepares to initiate Phase 3 development of PrimeC